Cell and ex vivo gene therapy: Advances in the treatment of central nervous system disorders;Terapia celular y terapia génica ex vivo: Avances en el tratamiento de enfermedades del sistema nervioso central

Revista de Neurologia

Volumn 49, Issue 9, 2009, Pages 483-489

  Mejia Toiber J ^a   Castillo, C G ^b   Giordano, Magda ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Cell lines; Dopamine; Epilepsy; GABA; Huntington's disease; Parkinson's disease; Transplants

Indexed keywords

4 AMINOBUTYRIC ACID; DOXYCYCLINE; LEVODOPA; OXIDOPAMINE; PILOCARPINE; VIRUS VECTOR;

CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL INTERACTION; CELL PROLIFERATION; CELL THERAPY; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; EPILEPSY; EPSTEIN BARR VIRUS; EX VIVO GENE TRANSFER; EXCITATION; GENETIC TRANSFORMATION; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NERVE DEGENERATION; NEUROSURGERY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; REVIEW; SURGICAL TECHNIQUE; TREATMENT INDICATION;

EID: 73949106288     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4909.2009176     Document Type: Review

References (71)

1. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 2000; 60: 409-70.
2. Nakao N, Itakura T. Fetal tissue transplants in animal models of Huntington's disease: the effects on damaged neuronal circuitry and behavioral deficits. Prog Neurobiol 2000; 61: 313-38.
3. Anton R, Kordower JH, Maidment NT, Manaster JS, Kane DJ, Rabizadeh S, et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp Neurol 1994; 127: 207-18.
4. Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant 2000; 9: 273-8.
5. Svendsen CN, Caldwell MA, Shen J, ter Borg MG, Rosser AE, Tyers P, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol 1997; 148: 135-46.
6. Ben-Ari Y. Cell death and synaptic reorganizations produced by seizures. Epilepsia 2001; 42 (Suppl 3): S5-7.
7. Gokhan S, Song Q, Mehler MF. Generation and regulation of developing immortalized neural cell lines. Methods 1998; 16: 345-58.
8. Conejero-Goldberg C, Tornatore C, Abi-Saab W, Monaco MC, Dillon-Carter O, Vawter M, et al. Transduction of human GAD67 cDNA into immortalized striatal cell lines using an Epstein-Barr virus-based plasmid vector increases GABA content. Exp Neurol 2000; 161: 453-61.
9. Loscher W, Gernert M, Heinemann U. Cell and gene therapies in epilepsy - promising avenues or blind alleys? Trends Neurosci 2008; 31: 62-73.
10. Thompson KW. Genetically engineered cells with regulatable GABA production can affect afterdischarges and behavioral seizures after transplantation into the dentate gyrus. Neuroscience 2005; 133: 1029-37.
11. González-Hoyuela M, González-Fraguela ME. La terapia genética para el sistema nervioso: una tendencia en la neurología moderna. Rev Neurol 1998; 27: 625-30.
12. Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci 2000; 3: 537-44.
13. Richardson RM, Barbaro NM, Álvarez-Buylla A, Baraban SC. Developing cell transplantation for temporal lobe epilepsy. Neurosurg Focus 2008; 24: 17.
14. Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathol 2008; 115: 385-98.
15. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 2005; 28: 86-92.
16. Mínguez-Castellanos A, Escamilla-Sevilla F. Terapia celular y otras estrategias neurorregenerativas en la enfermedad de Parkinson (II). Rev Neurol 2005; 41: 684-93.
17. Mínguez-Castellanos A, Escamilla-Sevilla F. Terapia celular y otras estrategias neurorregenerativas en la enfermedad de Parkinson (I). Rev Neurol 2005; 41: 604-14.
18. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008; 23: 2303-6.
19. Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35: 172-80.
20. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19: 102-9.
21. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-24.
22. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14: 507-9.
23. Freed WJ, Poltorak M, Becker JB. Intracerebral adrenal medulla grafts: a review. Exp Neurol 1990; 110: 139-66.
24. Kompoliti K, Chu Y, Shannon KM, Kordower JH. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord 2007; 22: 1630-3.
25. Curran EJ, Albin RL, Becker JB. Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function. J Neurosci 1993; 13: 3864-77.
26. Fisher LJ, Gage FH. Intracerebral transplantation: basic and clinical applications to the neostriatum. Faseb J 1994; 8: 489-96.
27. Cunningham LA, Short MP, Breakefield XO, Bohn MC. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Res 1994; 658: 219-31.
28. Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Res 1995; 691: 25-36.
29. Takayama H, Ray J, Raymon HK, Baird A, Hogg J, Fisher LJ, et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1995; 1: 53-8.
30. Rodríguez-Gómez JA, Lu JQ, Velasco I, Rivera S, Zoghbi SS, Liow JS, et al. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 2007; 25: 918-28.
31. O'Keeffe FE, Scott SA, Tyers P, O'Keeffe GW, Dalley JW, Zufferey R, et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain 2008; 131: 630-41.
32. Ryu MY, Lee MA, Ahn YH, Kim KS, Yoon SH, Snyder EY, et al. Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats. Cell Transplant 2005; 14: 193-202.
33. Bjorklund LM, Isacson O. Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. Prog Brain Res 2002; 138: 411-20.
34. Lu L, Zhao C, Liu Y, Sun X, Duan C, Ji M, et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res Brain Res Protoc 2005; 15: 46-51.
35. Martín-Aparicio E, Lucas JJ. Bases moleculares de la enfermedad de Huntington y posibles mecanismos patogénicos. Rev Neurol 2002; 35: 212-20.
36. Margolis RL, Ross CA. Diagnosis of Huntington disease. Clin Chem 2003; 49: 1726-32.
37. Melone MA, Jori FP, Peluso G. Huntington's disease: new frontiers for molecular and cell therapy. Curr Drug Targets 2005; 6: 43-56.
38. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991; 11: 1649-59.
39. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976; 263: 244-6.
40. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976; 263: 517-9.
41. García-Ramos R, Del Val-Fernández J, Catalán-Alonso MJ, Barcia-Albacar JA, Matías-Guiu J. Modelos experimentales de la enfermedad de Huntington. Rev Neurol 2007; 45: 437-41.
42. Alston TA, Mela L, Bright HJ. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci U S A 1977; 74: 3767-71.
43. Fricker-Gates RA, Lundberg C, Dunnett SB. Neural transplantation: restoring complex circuitry in the striatum. Restor Neurol Neurosci 2001; 19: 119-38.
44. Kendall AL, Rayment FD, Torres EM, Baker HF, Ridley RM, Dunnett SB. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998; 4: 727-9.
45. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995; 68: 273-85.
46. Isacson O, Brundin P, Kelly PA, Gage FH, Bjorklund A. Functional neuronal replacement by grafted striatal neurones in the ibotenic acidlesioned rat striatum. Nature 1984; 311: 458-60.
47. Dunnett SB, Isacson O, Sirinathsinghji DJ, Clarke DJ, Bjorklund A. Striatal grafts in rats with unilateral neostriatal lesions -III. Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching. Neuroscience 1988; 24: 813-20.
48. Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356: 1975-9.
49. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 2000; 97: 13877-82.
50. Keene CD, Sonnen JA, Swanson PD, Kopyov O, Leverenz JB, Bird TD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007; 68: 2093-8.
51. Bosch M, Pineda JR, Sunol C, Petriz J, Cattaneo E, Alberch J, et al. Induction of GABAergic phenotype in a neural stem cell line for transplantation in an excitotoxic model of Huntington's disease. Exp Neurol 2004; 190: 42-58.
52. Galpern WR, Matthews RT, Beal MF, Isacson O. NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease. Neuroreport 1996; 7: 2639-42.
53. Martínez-Serrano A, Bjorklund A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 1996; 16: 4604-16.
54. Emerich DF, Lindner MD, Winn SR, Chen EY, Frydel BR, Kordower JH. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 1996; 16: 5168-81.
55. Feron F. Current cell therapy strategies for repairing the central nervous system. Rev Neurol (Paris) 2007; 163 (Special 1): S23-30.
56. Vazey EM, Chen K, Hughes SM, Connor B. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease. Exp Neurol 2006; 199: 384-96.
57. Visnyei K, Tatsukawa KJ, Erickson RI, Simonian S, Oknaian N, Carmichael ST, et al. Neural progenitor implantation restores metabolic deficits in the brain following striatal quinolinic acid lesion. Exp Neurol 2006; 197: 465-74.
58. Scharfman HE. The neurobiology of epilepsy. Curr Neurol Neurosci Rep 2007; 7: 348-54.
59. Cossart R, Dinocourt C, Hirsch JC, Merchán-Pérez A, De Felipe J, Ben-Ari Y, et al. Dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy. Nat Neurosci 2001; 4: 52-62.
60. Barry DI, Kikvadze I, Brundin P, Bolwig TG, Bjorklund A, Lindvall O. Grafted noradrenergic neurons suppress seizure development in kindling-induced epilepsy. Proc Natl Acad Sci U S A 1987; 84: 8712-5.
61. Barry DI, Wanscher B, Kragh J, Bolwig TG, Kokaia M, Brundin P, et al. Grafts of fetal locus coeruleus neurons in rat amygdala-piriform cortex suppress seizure development in hippocampal kindling. Exp Neurol 1989; 106: 125-32.
62. Fine A, Meldrum BS, Patel S. Modulation of experimentally induced epilepsy by intracerebral grafts of fetal GABAergic neurons. Neuropsychologia 1990; 28: 627-34.
63. Ross KC, Waldman BC, Conejero-Goldberg C, Freed W, Coleman JR. Transplantation of M213-2O cells with enhanced GAD67 expression into the inferior colliculus alters audiogenic seizures. Exp Neurol 2002; 177: 338-40.
64. Castillo CG, Mendoza S, Freed WJ, Giordano M. Intranigral transplants of immortalized GABAergic cells decrease the expression of kainic acid-induced seizures in the rat. Behav Brain Res 2006; 171: 109-15.
65. Castillo CG, Mendoza-Trejo S, Aguilar MB, Freed WJ, Giordano M. Intranigral transplants of a GABAergic cell line produce long-term alleviation of established motor seizures. Behav Brain Res 2008; 193: 17-27.
66. Nolte MW, Loscher W, Herden C, Freed WJ, Gernert M. Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures. Neurobiol Dis 2008; 31: 342-54.
67. Thompson K, Anantharam V, Behrstock S, Bongarzone E, Campagnoni A, Tobin AJ. Conditionally immortalized cell lines, engineered to produce and release GABA, modulate the development of behavioral seizures. Exp Neurol 2000; 161: 481-9.
68. Thompson KW, Suchomelova LM. Transplants of cells engineered to produce GABA suppress spontaneous seizures. Epilepsia 2004; 45: 4-12.
69. Gernert M, Thompson KW, Loscher W, Tobin AJ. Genetically engineered GABA-producing cells demonstrate anticonvulsant effects and long-term transgene expression when transplanted into the central piriform cortex of rats. Exp Neurol 2002; 176: 183-92.
70. Kanter-Schlifke I, Fjord-Larsen L, Kusk P, Angehagen M, Wahlberg L, Kokaia M. GDNF released from encapsulated cells suppresses seizure activity in the epileptic hippocampus. Exp Neurol 2009.
71. Hattiangady B, Rao MS, Shetty AK. Grafting of striatal precursor cells into hippocampus shortly after status epilepticus restrains chronic temporal lobe epilepsy. Exp Neurol 2008; 212: 468-81.